Current Debates in Antiphospholipid Syndrome: The Acquired Antibody-Mediated Thrombophilia
Identifieur interne : 000250 ( an2020/Analysis ); précédent : 000249; suivant : 000251Current Debates in Antiphospholipid Syndrome: The Acquired Antibody-Mediated Thrombophilia
Auteurs : M. Akif Öztürk ; Ibrahim C. Haznedaro Lu [Turquie] ; Mehmet Turgut [Turquie] ; Hakan Göker [Turquie]Source :
- Clinical and Applied Thrombosis/Hemostasis [ 1076-0296 ] ; 2004-04.
English descriptors
- Teeft :
- Acas, Akif, Amengual, Anionic phospholipids, Annexin, Antibody, Antibody syndrome, Anticardiolipin, Anticardiolipin antibodies, Anticoagulant, Anticoagulation, Antigenic, Antiphospholipid, Antiphospholipid antibodies, Antiphospholipid antibody syndrome, Antiphospholipid syndrome, Antithrombotic, Apoptosis, Apoptotic, Apoptotic cells, Appl, Aptt, Arthritis rheum, Aspirin, Assay, Asymptomatic, Atsumi, Autoantibody, Autoimmun, Autoimmune, Beta, Bick, Cardiolipin, Cervera, Clin, Clin appl thromb hemost, Clin pathol, Clinical features, Clinical manifestations, Clinical significance, Coagulation, Coagulation cascade, Cofactor, Cohort, Confirmatory, Current debates, Drvvt, Elisa, Endothelial, Endothelial cells, Endothelium, Epitope, Erythematosus, Fetal, Fetal loss, Gharavi, Glycoprotein, Gonadotropin, Gynecol, Haematol, Haemost, Hematol, Hemost, Hemostasis, Heparin, Hypertension, Immune, Immunoglobulin, Immunol, Immunologic, Infarction, Intravenous, Invasiveness, Ischemic, Isotype, Ivig, Kaolin, Khamashta, Laboratory diagnosis, Lipid, Lipoprotein, Lmwh, Lupus, Lupus anticoagulant, Lupus anticoagulants, Miscarriage, Monoclonal, Monocyte, Myocardial infarction, Neurologic, Normal plasma, Obstet, Obstet gynecol, Obstetric, Other hand, Oxidative, Oxidized, Pathobiology, Pathogenesis, Pathol, Pathway, Phosphatidylethanolamine, Phosphatidylserine, Phospholipid, Pierangeli, Placenta, Placental, Placental thrombosis, Platelet, Platelet activation, Pregnancy loss, Primary antiphospholipid syndrome, Procoagulant, Prophylaxis, Prothrombin, Prothrombotic, Randomized, Reprod, Rheum, Rheumatol, Rheumatology, Standardization, Subgroup, Suppl, Syndrome, Syndrome patients, Systemic, Systemic lupus erythematosus, Thromb, Thromb haemost, Thrombin, Thrombocytopenia, Thromboembolism, Thrombophilia, Thromboplastin, Thrombosis, Thrombotic, Thrombotic events, Thrombus, Tissue factor, Tissue factor pathway, Triplett, Trophoblast, Venous, Venous thrombosis, Viper, Warfarin.
Abstract
Antiphospholipid (APL) syndrome is the most common form of acquired thrombophilia. It can cause significant morbidity and even mortality. The term “APL antibodies” represents a heterogeneous group of antibodies associated with this disorder. Currently no single assay can identify every APL antibody. Clinically relevant APL antibodies are mainly anticardiolipin antibodies (ACA) detected by solid phase enzyme-linked immunosorbent assay (ELISA) and lupus anticoagulants (LA) demonstrated by in vitro coagulation assay. However, there are some other antibodies associated with the APL syndrome (i.e., subgroup APL antibodies). ACAs, LAs, and subgroup APL antibodies represent intersecting, but non-identical, subsets of autoantibodies. Thus, those autoantibodies may coexist or may occur independently. Any organ system and any size of vessel can be affected during the clinical course of the disease. Therefore, the APL syndrome can manifest itself in a wide variety of clinical thrombotic features. Fetal loss and pregnancy morbidity represent a specific challenge. Despite tremendous advances in the understanding of the pathogenesis of APL syndrome during the past decade, the mainstay of management is still anticoagulation. However, there is no general agreement regarding the duration and intensity of anticoagulant therapy. In this review, we focused on the current dilemmas and their present clarifications in the wide clinicopathologic spectrum of APL syndrome and APL antibody-related distinct pathologic conditions.
Url:
DOI: 10.1177/107602960401000201
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002031
- to stream Istex, to step Curation: 002031
- to stream Istex, to step Checkpoint: 000E46
- to stream Main, to step Merge: 002020
- to stream Main, to step Curation: 002005
- to stream Main, to step Exploration: 002005
- to stream an2020, to step Extraction: 000250
Links to Exploration step
ISTEX:B827091BEADC215794937213345837B0228A0FE5Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Current Debates in Antiphospholipid Syndrome: The Acquired Antibody-Mediated Thrombophilia</title><author wicri:is="90%"><name sortKey="Ozturk, M Akif" sort="Ozturk, M Akif" uniqKey="Ozturk M" first="M. Akif" last="Öztürk">M. Akif Öztürk</name></author><author wicri:is="90%"><name sortKey="Haznedaro Lu, Ibrahim C" sort="Haznedaro Lu, Ibrahim C" uniqKey="Haznedaro Lu I" first="Ibrahim C." last="Haznedaro Lu">Ibrahim C. Haznedaro Lu</name></author><author wicri:is="90%"><name sortKey="Turgut, Mehmet" sort="Turgut, Mehmet" uniqKey="Turgut M" first="Mehmet" last="Turgut">Mehmet Turgut</name></author><author wicri:is="90%"><name sortKey="Goker, Hakan" sort="Goker, Hakan" uniqKey="Goker H" first="Hakan" last="Göker">Hakan Göker</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:B827091BEADC215794937213345837B0228A0FE5</idno><date when="2004" year="2004">2004</date><idno type="doi">10.1177/107602960401000201</idno><idno type="url">https://api.istex.fr/ark:/67375/M70-T6B88BCZ-M/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">002031</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002031</idno><idno type="wicri:Area/Istex/Curation">002031</idno><idno type="wicri:Area/Istex/Checkpoint">000E46</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000E46</idno><idno type="wicri:doubleKey">1076-0296:2004:Ozturk M:current:debates:in</idno><idno type="wicri:Area/Main/Merge">002020</idno><idno type="wicri:Area/Main/Curation">002005</idno><idno type="wicri:Area/Main/Exploration">002005</idno><idno type="wicri:Area/an2020/Extraction">000250</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Current Debates in Antiphospholipid Syndrome: The Acquired Antibody-Mediated Thrombophilia</title><author wicri:is="90%"><name sortKey="Ozturk, M Akif" sort="Ozturk, M Akif" uniqKey="Ozturk M" first="M. Akif" last="Öztürk">M. Akif Öztürk</name><affiliation><wicri:noCountry code="subField">Rheumatology</wicri:noCountry></affiliation></author><author wicri:is="90%"><name sortKey="Haznedaro Lu, Ibrahim C" sort="Haznedaro Lu, Ibrahim C" uniqKey="Haznedaro Lu I" first="Ibrahim C." last="Haznedaro Lu">Ibrahim C. Haznedaro Lu</name><affiliation wicri:level="1"><country xml:lang="fr">Turquie</country><wicri:regionArea>Hacettepe University School of Medicine, Department of Hematology, Ankara</wicri:regionArea><wicri:noRegion>Ankara</wicri:noRegion></affiliation></author><author wicri:is="90%"><name sortKey="Turgut, Mehmet" sort="Turgut, Mehmet" uniqKey="Turgut M" first="Mehmet" last="Turgut">Mehmet Turgut</name><affiliation wicri:level="1"><country xml:lang="fr">Turquie</country><wicri:regionArea>Hacettepe University School of Medicine, Department of Hematology, Ankara</wicri:regionArea><wicri:noRegion>Ankara</wicri:noRegion></affiliation></author><author wicri:is="90%"><name sortKey="Goker, Hakan" sort="Goker, Hakan" uniqKey="Goker H" first="Hakan" last="Göker">Hakan Göker</name><affiliation wicri:level="1"><country xml:lang="fr">Turquie</country><wicri:regionArea>Hacettepe University School of Medicine, Department of Hematology, Ankara</wicri:regionArea><wicri:noRegion>Ankara</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Clinical and Applied Thrombosis/Hemostasis</title><idno type="ISSN">1076-0296</idno><idno type="eISSN">1938-2723</idno><imprint><publisher>Sage Publications</publisher><pubPlace>Sage CA: Thousand Oaks, CA</pubPlace><date type="published" when="2004-04">2004-04</date><biblScope unit="volume">10</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="89">89</biblScope><biblScope unit="page" to="126">126</biblScope></imprint><idno type="ISSN">1076-0296</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1076-0296</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Acas</term><term>Akif</term><term>Amengual</term><term>Anionic phospholipids</term><term>Annexin</term><term>Antibody</term><term>Antibody syndrome</term><term>Anticardiolipin</term><term>Anticardiolipin antibodies</term><term>Anticoagulant</term><term>Anticoagulation</term><term>Antigenic</term><term>Antiphospholipid</term><term>Antiphospholipid antibodies</term><term>Antiphospholipid antibody syndrome</term><term>Antiphospholipid syndrome</term><term>Antithrombotic</term><term>Apoptosis</term><term>Apoptotic</term><term>Apoptotic cells</term><term>Appl</term><term>Aptt</term><term>Arthritis rheum</term><term>Aspirin</term><term>Assay</term><term>Asymptomatic</term><term>Atsumi</term><term>Autoantibody</term><term>Autoimmun</term><term>Autoimmune</term><term>Beta</term><term>Bick</term><term>Cardiolipin</term><term>Cervera</term><term>Clin</term><term>Clin appl thromb hemost</term><term>Clin pathol</term><term>Clinical features</term><term>Clinical manifestations</term><term>Clinical significance</term><term>Coagulation</term><term>Coagulation cascade</term><term>Cofactor</term><term>Cohort</term><term>Confirmatory</term><term>Current debates</term><term>Drvvt</term><term>Elisa</term><term>Endothelial</term><term>Endothelial cells</term><term>Endothelium</term><term>Epitope</term><term>Erythematosus</term><term>Fetal</term><term>Fetal loss</term><term>Gharavi</term><term>Glycoprotein</term><term>Gonadotropin</term><term>Gynecol</term><term>Haematol</term><term>Haemost</term><term>Hematol</term><term>Hemost</term><term>Hemostasis</term><term>Heparin</term><term>Hypertension</term><term>Immune</term><term>Immunoglobulin</term><term>Immunol</term><term>Immunologic</term><term>Infarction</term><term>Intravenous</term><term>Invasiveness</term><term>Ischemic</term><term>Isotype</term><term>Ivig</term><term>Kaolin</term><term>Khamashta</term><term>Laboratory diagnosis</term><term>Lipid</term><term>Lipoprotein</term><term>Lmwh</term><term>Lupus</term><term>Lupus anticoagulant</term><term>Lupus anticoagulants</term><term>Miscarriage</term><term>Monoclonal</term><term>Monocyte</term><term>Myocardial infarction</term><term>Neurologic</term><term>Normal plasma</term><term>Obstet</term><term>Obstet gynecol</term><term>Obstetric</term><term>Other hand</term><term>Oxidative</term><term>Oxidized</term><term>Pathobiology</term><term>Pathogenesis</term><term>Pathol</term><term>Pathway</term><term>Phosphatidylethanolamine</term><term>Phosphatidylserine</term><term>Phospholipid</term><term>Pierangeli</term><term>Placenta</term><term>Placental</term><term>Placental thrombosis</term><term>Platelet</term><term>Platelet activation</term><term>Pregnancy loss</term><term>Primary antiphospholipid syndrome</term><term>Procoagulant</term><term>Prophylaxis</term><term>Prothrombin</term><term>Prothrombotic</term><term>Randomized</term><term>Reprod</term><term>Rheum</term><term>Rheumatol</term><term>Rheumatology</term><term>Standardization</term><term>Subgroup</term><term>Suppl</term><term>Syndrome</term><term>Syndrome patients</term><term>Systemic</term><term>Systemic lupus erythematosus</term><term>Thromb</term><term>Thromb haemost</term><term>Thrombin</term><term>Thrombocytopenia</term><term>Thromboembolism</term><term>Thrombophilia</term><term>Thromboplastin</term><term>Thrombosis</term><term>Thrombotic</term><term>Thrombotic events</term><term>Thrombus</term><term>Tissue factor</term><term>Tissue factor pathway</term><term>Triplett</term><term>Trophoblast</term><term>Venous</term><term>Venous thrombosis</term><term>Viper</term><term>Warfarin</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Antiphospholipid (APL) syndrome is the most common form of acquired thrombophilia. It can cause significant morbidity and even mortality. The term “APL antibodies” represents a heterogeneous group of antibodies associated with this disorder. Currently no single assay can identify every APL antibody. Clinically relevant APL antibodies are mainly anticardiolipin antibodies (ACA) detected by solid phase enzyme-linked immunosorbent assay (ELISA) and lupus anticoagulants (LA) demonstrated by in vitro coagulation assay. However, there are some other antibodies associated with the APL syndrome (i.e., subgroup APL antibodies). ACAs, LAs, and subgroup APL antibodies represent intersecting, but non-identical, subsets of autoantibodies. Thus, those autoantibodies may coexist or may occur independently. Any organ system and any size of vessel can be affected during the clinical course of the disease. Therefore, the APL syndrome can manifest itself in a wide variety of clinical thrombotic features. Fetal loss and pregnancy morbidity represent a specific challenge. Despite tremendous advances in the understanding of the pathogenesis of APL syndrome during the past decade, the mainstay of management is still anticoagulation. However, there is no general agreement regarding the duration and intensity of anticoagulant therapy. In this review, we focused on the current dilemmas and their present clarifications in the wide clinicopathologic spectrum of APL syndrome and APL antibody-related distinct pathologic conditions.</div></front></TEI><affiliations><list><country><li>Turquie</li></country></list><tree><noCountry><name sortKey="Ozturk, M Akif" sort="Ozturk, M Akif" uniqKey="Ozturk M" first="M. Akif" last="Öztürk">M. Akif Öztürk</name></noCountry><country name="Turquie"><noRegion><name sortKey="Haznedaro Lu, Ibrahim C" sort="Haznedaro Lu, Ibrahim C" uniqKey="Haznedaro Lu I" first="Ibrahim C." last="Haznedaro Lu">Ibrahim C. Haznedaro Lu</name></noRegion><name sortKey="Goker, Hakan" sort="Goker, Hakan" uniqKey="Goker H" first="Hakan" last="Göker">Hakan Göker</name><name sortKey="Turgut, Mehmet" sort="Turgut, Mehmet" uniqKey="Turgut M" first="Mehmet" last="Turgut">Mehmet Turgut</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/an2020/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000250 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/an2020/Analysis/biblio.hfd -nk 000250 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= an2020
|étape= Analysis
|type= RBID
|clé= ISTEX:B827091BEADC215794937213345837B0228A0FE5
|texte= Current Debates in Antiphospholipid Syndrome: The Acquired Antibody-Mediated Thrombophilia
}}
| This area was generated with Dilib version V0.6.33. |  |